America's First Exclusively Orphan Drug Company:

Helpful Links

American Cancer Society (ACS)
The ACS is a nationwide community-based voluntary health organization. Its website and the ACS free phone line provide information on cancer treatment, early detection, and prevention, as well as cancer statistics and information on a variety of services available to cancer patients and their families.

Asian Pacific Islander Cancer Education Materials Tool
This tool provides links to cancer-related information resources in Asian and Pacific Islander languages.

Cancer.Net
This site for patients, their families, and friends is provided by the American Society of Clinical Oncology (ASCO). The site has an overview of cancer as well as detailed information on many types of cancer. It also gives access to ASCO resources, including treatment guidelines and research abstracts from annual ASCO meetings.

CureSearch
This site, a joint project of the Children’s Oncology Group and the National Childhood Cancer Foundation, offers an overview of childhood cancer as well as specific information for childhood cancer patients, their families, and health professionals.

healthfinder.gov
The U.S. Department of Health and Human Services’ healthfinder® is a free gateway to reliable consumer health information. It links to online publications, clearinghouses, databases, websites, and support and self-help groups, as well as to government agencies and nonprofit organizations that produce reliable information for the public.

LIVESTRONG
LIVESTRONG provides services and resources to people and families affected by cancer and empowers communities to take action in the fight against this disease. Its website includes information on a broad range of cancer survivorship topics, including physical, emotional, and practical topics.

MedlinePlus: Cancers
This is a cancer-specific section of MedlinePlus, an online service of the National Library of Medicine. MedlinePlus gives access to medical literature and other health information and has numerous links to other sites.

OncoLink
OncoLink, from the Abramson Cancer Center of the University of Pennsylvania, presents cancer information for patients and health care professionals.

American Cancer Society (ACS): Statistics
This resource is part of the main ACS website. It offers statistics on cancer occurrence, including the number of deaths and cases, and how long people survive after diagnosis.

CDC: National Program of Cancer Registries (NPCR)
State and national cancer data from NPCR and other sources.

American Association for Cancer Research (AACR)
AACR is a scientific society of laboratory and clinical cancer researchers. Its website contains information on AACR membership, meetings, journals, and conferences.

American Society of Clinical Oncology (ASCO)
ASCO is a professional organization of health-care practitioners who have a predominant interest in oncology. Its website includes links to publications and information on clinical practice guidelines and ASCO meetings and policies.

American Society of Clinical Oncology (ASCO): Abstracts
Search the American Society of Clinical Oncology’s (ASCO’s) database of annual meeting abstracts of clinical cancer research results.

National Institutes of Health (NIH)
NIH is a component of the U.S. Department of Health and Human Services. It consists of 27 institutes and centers that conduct medical research for the Federal Government.

INDICATION

PURIXAN® (mercaptopurine) is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as a component of a combination maintenance therapy regimen.

Warnings and Precautions

Myelosuppression
Monitor complete blood count (CBC) and adjust the dose of PURIXAN for excessive myelosuppression. Consider testing in patients with severe myelosuppression or repeated episodes of myelosuppression for thiopurine S-methyltransferase (TPMT) or nucleotide diphosphatase (NUDT15) deficiency. Patients with homozygous-TPMT or homozygous-NUDT15 deficiency may require a dose reduction.

Hepatotoxicity
Monitor transaminases, alkaline phosphatase and bilirubin. Withhold PURIXAN at onset of hepatotoxicity.

Immunosuppression
Response to all vaccines may be diminished and there is a risk of infection with live virus vaccines. Consult immunization guidelines for immunocompromised pediatrics.

Treatment Related Malignancies
Aggressive and fatal cases of hepatosplenic T-cell lymphoma have occurred.

Macrophage Activation Syndrome
Monitor for and treat promptly; discontinue PURIXAN.

Embryo-Fetal Toxicity
Can cause fetal harm. Advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception.

 

Adverse Reactions

Adverse Reactions – Clinical Studies Experience
The most common adverse reaction occurring in > 20% of patients was myelosuppression, including anemia, neutropenia, lymphopenia and thrombocytopenia. Adverse reactions occurring in 5% to 20 % of patients included anorexia, nausea, vomiting, diarrhea, malaise, and rash. Adverse reactions occurring in < 5 % of patients included urticaria, hyperuricemia, oral lesions, elevated transaminases, hyperbilirubinemia, hyperpigmentation, infections, and pancreatitis. Oral lesions resemble thrush rather than antifolic ulcerations. Delayed or late toxicities include hepatic fibrosis, hyperbilirubinemia, alopecia, pulmonary fibrosis, oligospermia and secondary malignancies.

Adverse Reactions – Postmarketing Experience
The following adverse reactions have been identified during postapproval use of PURIXAN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions include: photosensitivity, hypoglycemia, and portal hypertension.

See Full Prescribing Information

Privacy Statement & Terms of Use | PUR-Web-013-ADM | July 2020